Exact Sciences Corporation Profile Avatar - Palmy Investing

Exact Sciences Corporation

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated wit…
Medical - Diagnostics & Research
US, Madison [HQ]
EXAS/Leadership and Strategy

Risk Factors

By Management
10-K
  1. The FDA may change its position with respect to its regulation of the laboratory developed tests we offer or may seek to offer in the future, causing us to incur substantial costs and time delays associated with meeting requirements for pre-market clearance or approval or we could experience decreased demand for or reimbursement of our tests.

  2. We rely on courier delivery services to transport Cologuard collection kits to patients and samples for all of our tests back to laboratory facilities for analysis. If these delivery services are disrupted or become significantly more expensive, customer satisfaction and our business could be negatively impacted.

  3. The success of our Cologuard test, our Precision Oncology tests, and any other screening or diagnostic product or service we offer or develop will depend on the degree of market acceptance by healthcare providers, patients, healthcare payers, and others in the medical community.

16 more risks
End of EXAS's Analysis
CIK: 1124140 CUSIP: 30063P105 ISIN: US30063P1057 LEI: - UEI: -
Secondary Listings
EXAS has no secondary listings inside our databases.